Cytek Biosciences, Inc. (CTKB)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Cytek Biosciences, Inc. currently loses $25.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc. (NASDAQ: CTKB) makes cell analysis instruments and related consumables and software for the healthcare equipment market. Its spectrum flow cytometry and cell sorting platform serves biomedical research and clinical settings, and the company recorded $201.5 million of revenue in FY2025.
Today's Snapshot
CTKB opened 0.8% lower at 4.69, while its sector was flat. Cytek Biosciences announced a European collaboration with Sysmex Europe, a diagnostics company.
Trading Volume
Below 10d avg (614.2K)
118.5K
vs S&P 500 Today
Underperforming Market
-1.57%
Updated: September 10, 2026 at 14:40 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.48 - $4.66Buy
- RSI (14)50.39Neutral
- Stochastic %K (14, 3, 3)64.43Neutral
- MACD Level (12, 26)0.04Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.